Refractory asthma - Beyond step 5, the role of new and emerging adjuvant therapies

Chronic Respiratory Disease

Volumn 12, Issue 1, 2015, Pages 69-77

  Kane, Binita ^a   Fowler, Stephen J ^a,b   Niven, Rob ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b LANCASHIRE TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

asthma; novel; Refractory; therapy

Indexed keywords

ANTIFUNGAL AGENT; BRONCHODILATING AGENT; MONOCLONAL ANTIBODY; MUCOLYTIC AGENT; PHOSPHODIESTERASE IV INHIBITOR; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; ANTIASTHMATIC AGENT; ANTIIDIOTYPIC ANTIBODY; DUPILUMAB; INTERLEUKIN 4; ITRACONAZOLE; LEBRIKIZUMAB; MACROLIDE; MEPOLIZUMAB; OMALIZUMAB; PITRAKINRA; TRALOKINUMAB; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT THERAPY; ASTHMA; BODY WEIGHT DISORDER; BRONCHIAL THERMOPLASTY DEVICE; CLINICAL ASSESSMENT; HUMAN; INFLAMMATION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; ANTAGONISTS AND INHIBITORS; BRONCHOSCOPY; BRONCHUS; FUNGUS; HYPERSENSITIVITY; HYPERTHERMIC THERAPY; IMMUNOLOGY; PROCEDURES; SURGERY; TREATMENT FAILURE;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIFUNGAL AGENTS; ASTHMA; BRONCHI; BRONCHODILATOR AGENTS; BRONCHOSCOPY; FUNGI; HUMANS; HYPERSENSITIVITY; HYPERTHERMIA, INDUCED; INTERLEUKIN-4; ITRACONAZOLE; MACROLIDES; PHOSPHODIESTERASE 4 INHIBITORS; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84921454779     PISSN: 14799723     EISSN: 14799731     Source Type: Journal    
DOI: 10.1177/1479972314562210     Document Type: Review

References (71)

1. British guideline on the management of asthma. Thorax. 2008 ; 63 (Suppl 4). iv1-121
2. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med. 2000 ; 162 (6). 2341-2351
3. Papiris S, Kotanidou A, Malagari K, et al. Clinical review: severe asthma. Crit Care. 2002 ; 6 ((1)). 30-44
4. Sweeney J, Brightling CE, Menzies-Gow A, et al. Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry. Thorax. 2012 ; 67 ((8)). 754-756
5. Taylor DR, Bateman ED, Boulet LP, et al. A new perspective on concepts of asthma severity and control. Eur Respir J. 2008 ; 32 ((3)). 545-554
6. Global Strategy for Asthma Management. Available at: http://www.ginasthma.org/documents/4(2013, accessed 28 November 2014).
7. Carter PM, Heinly TL, Yates SW, et al. Asthma: the irreversible airways disease. J Investig Allergol Clin Immunol. 1997 ; 7 ((6)). 566-571
8. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002 ; 360 ((9347)). 1715-1721
9. Hastie AT, Moore WC, Meyers DA, et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol. 2010 ; 125 ((5)). 1028-1036
10. Moore WC, Hastie AT, Li X, et al. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol. 2014 ; 133 ((6)). 1557-1563
11. Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest. 2001 ; 119 ((5)). 1329-1336
12. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008 ; 178 ((3)). 218-224
13. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010 ; 181 ((4)). 315-323
14. Bolanos SH, Khan DA, Hanczyc M, et al. Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales. Ann Allergy Asthma Immunol. 2004 ; 92 ((5)). 500-505
15. Gibeon D, Batuwita K, Osmond M, et al. Obesity-associated severe asthma represents a distinct clinical phenotype: analysis of the British Thoracic Society Difficult Asthma Registry Patient Cohort according to BMI. Chest. 2013 ; 143 ((2)). 406-414
16. Diaz RA, Charles Z, George E, et al. NICE guidance on omalizumab for severe asthma. Lancet Respir Med. 2013 ; 1 ((3)). 189-190
17. Burton A, Hargadon B, Murphy A, et al. The eligibility of patients with difficult asthma for omalizumab since the change to the treatment criteria. Thorax. 2010 ; 65: A84 - A85
18. Barnes N, Menzies-Gow A, Mansur AH, et al. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study. J Asthma. 2013 ; 50 ((5)). 529-536
19. Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010 ; 181 ((2)). 116-124
20. NICE IPG419: Bronchial Thermoplasty in Severe Asthma. Available at: http://publications.nice.org.uk/bronchial-thermoplasty-for-severe-asthma-ipg419(2012, accessed 28 November 2014).
21. Chung KF, Barnes PJ. Cytokines in asthma. Thorax. 1999 ; 54 ((9)). 825-857
22. Comet R, Domingo C, Larrosa M, et al. Benefits of low weekly doses of methotrexate in steroid-dependent asthmatic patients. A double-blind, randomized, placebo-controlled study. Respir Med. 2006 ; 100 ((3)). 411-419
23. Domingo RC, Comet MR, Bosque GM, et al. Efficiency of methotrexate in the treatment of cortico-dependent asthmatic patients. Rev Clin Esp. 1999 ; 199 ((3)). 142-146
24. Denning DW, O'Driscoll BR, Powell G, et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: the Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med. 2009 ; 179 ((1)). 11-18
25. Agbetile J, Bourne M, Fairs A, et al. Effectiveness of voriconazole in the treatment of Aspergillus fumigatus-associated asthma (EVITA3 study). J Allergy Clin Immunol. 2013 ; (13). 10
26. Richeldi L, Ferrara G, Fabbri LM, et al. Macrolides for chronic asthma. Cochrane Database Syst Rev. 2005 ; (4). CD002997
27. Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2008 ; 177 ((2)). 148-155
28. Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013 ; 68 ((4)). 322-329
29. Nair P, Gaga M, Zervas E, et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy. 2012 ; 42 ((7)). 1097-1103
30. Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013 ; 188 (11). 1294-1302
31. Kellett F, Redfern J, Niven RM. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir Med. 2005 ; 99 ((1)). 27-31
32. Sutton PP, Gemmell HG, Innes N, et al. Use of nebulised saline and nebulised terbutaline as an adjunct to chest physiotherapy. Thorax. 1988 ; 43 ((1)). 57-60
33. Wilkinson M, Sugumar K, Milan SJ, et al. Mucolytics for bronchiectasis. Cochrane Database Syst Rev. 2014 ; 5: CD001289
34. Daviskas E, Anderson SD, Eberl S, et al. Beneficial effect of inhaled mannitol and cough in asthmatics with mucociliary dysfunction. Respir Med. 2010 ; 104 ((11)). 1645-1653
35. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax. 2005 ; 60 ((12)). 1012-1018
36. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med. 2006 ; 354 ((7)). 697-708
37. Morjaria JB, Chauhan AJ, Babu KS, et al. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax. 2008 ; 63 ((7)). 584-591
38. Holgate ST, Noonan M, Chanez P, et al. Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur Respir J. 2011 ; 37 ((6)). 1352-1359
39. Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009 ; 179 ((7)). 549-558
40. Gauvreau GM, Boulet LP, Schmid-Wirlitsch C, et al. Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects. Respir Res. 2011 ; 140: 12
41. Bateman ED, Izquierdo JL, Harnest U, et al. Efficacy and safety of roflumilast in the treatment of asthma. Ann Allergy Asthma Immunol. 2006 ; 96 ((5)). 679-686
42. Bateman ED, Rabe KF, Calverley PM, et al. Roflumilast with long-acting beta2-agonists for COPD: influence of exacerbation history. Eur Respir J. 2011 ; 38 ((3)). 553-560
43. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002 ; 360 ((9347)). 1715-1721
44. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med. 1999 ; 160 ((3)). 1001-1008
45. Rothenberg ME, Hogan SP. The Eosinophil. Ann Rev Immunol. 2006 ; 24 ((1)). 147-174
46. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009 ; 360 ((10)). 973-984
47. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009 ; 360 ((10)). 985-993
48. Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011 ; 184 ((10)). 1125-1132
49. Castro M, Gossage D, Ward C, et al. Benralizumab reduces exacerbations and improves lung function in adults with uncontrolled eosinophilic asthma. Am J Respir Crit Care Med. 2014 ; B101: A3699
50. Luttmann W, Knoechel B, Foerster M, et al. Activation of human eosinophils by IL-13. Induction of CD69 surface antigen, its relationship to messenger RNA expression, and promotion of cellular viability. J Immunol. 1996 ; 157 ((4)). 1678-1683
51. Venkayya R, Lam M, Willkom M, et al. The Th2 lymphocyte products IL-4 and IL-13 rapidly induce airway hyperresponsiveness through direct effects on resident airway cells. Am J Respir Cell Mol Biol. 2002 ; 26 ((2)). 202-208
52. Berry MA, Parker D, Neale N, et al. Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. J Allergy Clin Immunol. 2004 ; 114 ((5)). 1106-1109
53. Noonan M, Korenblat P, Mosesova S, et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol. 2013 ; 132 ((3)). 567-574
54. Singh D, Kane B, Molfino NA, et al. A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. BMC Pulm Med. 2010 ; 3: 10
55. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011 ; 365 ((12)). 1088-1098
56. Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet. 2007 ; 370 ((9596)). 1422-1431
57. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 ; 368 ((26)). 2455-2466
58. Kanazawa H. Anticholinergic agents in asthma: chronic bronchodilator therapy, relief of acute severe asthma, reduction of chronic viral inflammation and prevention of airway remodeling. Curr Opin Pulm Med. 2006 ; 12 ((1)). 60-67
59. Novelli F, Costa F, Latorre M, et al. Tiotropium: a new therapeutic option in asthma. Monaldi Arch Chest Dis. 2013 ; 79 ((3-4)). 109-115
60. Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010 ; 363 ((18)). 1715-1726
61. Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012 ; 367 ((13)). 1198-1207
62. Befekadu E, Onofrei C, Colice GL. Tiotropium in asthma: a systematic review. J Asthma Allergy. 2014 ; 7: 11-21
63. Bateman ED, O'Byrne PM, Busse WW, et al. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax. 2014 ; 69 ((4)). 312-319
64. Cazzola M, Rogliani P, Segreti A, et al. An update on bronchodilators in Phase I and II clinical trials. Expert Opin Investig Drugs. 2012 ; 21 ((10)). 1489-1501
65. Pavord ID, Thomson NC, Niven RM, et al. Safety of bronchial thermoplasty in patients with severe refractory asthma. Ann Allergy Asthma Immunol. 2013 ; 111 ((5)). 402-407
66. Wechsler ME, Laviolette M, Rubin AS, et al. Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol. 2013 ; 132 ((6)). 1295-1302
67. Franciosi LG, Diamant Z, Banner KH, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med. 2013 ; 1 (9). 714-727
68. Duan W, Chan JHP, McKay K, et al. Inhaled p38{alpha} mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am J Respir Crit Care Med. 2005 ; 171 ((6)). 571-578
69. Edwards MR, Bartlett NW, Clarke D, et al. Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther. 2009 ; 121 ((1)). 1-13
70. Barnes PJ. Glucocorticosteroids: current and future directions. Br J Pharmacol. 2011 ; 163 ((1)). 29-43
71. Bareille P, Hardes K, Donald AC. Efficacy and safety of once-daily GW870086 a novel selective glucocorticoid in mild-moderate asthmatics: a randomised, two-way crossover, controlled clinical trial. J Asthma. 2013 ; 50 ((10)). 1077-1082